ABSTRACT
Renal function measurement and renal imaging using radionuclidic methods have a long history. Since 1950s, estimation of glomerular function and tubular function were possible using several radiopharmaceuticals. Later, scintigraphic imaging of kidneys, ureters and bladder were carried out. This review discusses the devolepment and evoluation of the nuclear medicine methods for the estimation and imaging of nephrourologic function.
References
1Braasch W. Pyelography. W B Saunders Company, Philadelphia, PA, 1915.
2Evans J, Monteith J, Dubilier W. Nephrotomography. Radiology 1955; 64: 655-663.
3Hutch J. Vesico-ureteral reflux in the paraplegic: cause and correction. J. Urol. 1952; 68: 457-467.
4Taplin G, Meredith O Jr, Kade H, Winter C. The radioisotope renogram. J. Lab. Clin. Med. 1956; 481: 886-901.
5McAfee JG, Wagner HN Jr. Visualization of renal parenchyma by scintiscanning with Hg203 neohydrin. Radiology 1960;75: 820-821.
6Reba RC, McAffee JG, Wagner HN Jr. Radiomercury-labelled chlormerodrin for in vivo uptake studies and scintillation scanning of unilateral renal lesions associated with hypertension. Medicine (Baltimore). 1963;42:269-296.
7Brooks RT Jr, Dettman PM, Galuzska AA. Renal scans in urologic diagnosis using neohydrin Hg-203. J Urol 1963;90:107-112.
8Taplin GV, Dore EK, Johnson DE. The quantitative radiorenogram for total and differential renal blood flow measurements. UCLA-514. UCLA Rep. 1963;86:1-18.
9Yasky J, Volpe R. An assessment of the “radioactive renogram” using O-iodohippurate sodium (Hippuran) labelled with radioactive iodine. Can Med Assoc J 1963;88:1055-1064.
10Wenzl JE, Tauxe WN, Hunt JC. A single-injection technic for renal photoscanning with ortho-iodohippurate-I-131. A preliminary report. Proc Staff Meet Mayo Clin 1963 17;38:313-320.
11Doig A, Lawrence JR, Philip T, Tothill P, Donald KW. 131-I-”Hippuran” renography in detection of unilateral renal disease in patients with hypertension. Br Med J 1963;1:500-504.
12Burbank MK, Hunt JC, Tauxe WN, Maher FT. Radioisotopic renography. Diagnosis of renal arterial disease in hypertensive patients. Circulation 1963;27:328-338.
13Blaufox MD, Frohmuller HG, Campell JC, Utz DC, Orvis AL, Owen CA Jr. Simplified method of estimating renal function with iodohippurate I-131. J Surg Res. 1963;3:122-125.
14Brown NJG, Britton KE. The renogram and its quantitation. Br J Urol 1969;41:15-25
15Skov PE. Glomerular filtration rate in patients with severe and very severe renal insufficiency. Determined by simultaneous inulin, creatinine and 125 iothalamate clearance. Acta Med Scand 1970;187:419-428.
16Wiener SN, Shah YP, Mares RM, Flynn MJ. Correlation of I-125 iothalamate and tc-99m DPTA measurements of GFR using the single injection method. Clin Nucl Med 1982;7:359-363.
17Rado JP, Banos C, Tako J, Szende I. Renographic studies during furosemide diuresis in partial ureteral obstruction. Radiol Clin Biol 1969; 38: 132-146.
18O’Reiily PH, Testa HJ, Lawson RS, Farrar DJ, Edwards EC. Diuresis renography in equivocal urinary tract obstruction. Br J Urol 1978; 50: 76-90.
19Koff SA, ThrallJH, Keyes JW. Diuretic radionuclide urography: a noninvasive method for evaluating nephrouretheral dilatation. J Urol 1979; 122:451-454.
20Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med. 1986 ;27:111-116.
21Taylor A Jr, Eshima D, Fritzberg AR, Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med 1986;27:795-803.
22Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med. 1993;20:738-746.
23Stoffel M, Jamar F, Van Nerom C, Verbruggen A, Mourad M, Leners N, Squifflet JP, Beckers C. Evaluation of technetium-99m-L,L-EC in renal transplant recipients: a comparative study with technetium-99m-MAG3 and iodine-125-OIH. J Nucl Med. 1994;35:1951-1958.
24Bubeck B, Piepenburg R, Grethe U, Ehrig B, Hahn K. A new principle to normalize plasma concentrations allowing single-sample clearance determinations in both children and adults. Eur J Nucl Med 1992;19:511-516.
25Kotzerke J, Glatz S, Grillenberger K, Kleinschmidt K, Reske SN. Reproducibility of a single-sample method for 99Tcm-MAG3 clearance under clinical conditions. Nucl Med Commun;18:352-357.
26Ozker K, Onsel C, Kabasakal L, ve ark. Technetium-99m-N,N-ethylenedicysteine--a comparative study of renal scintigraphy with technetium-99m-MAG3 and iodine-131-OIH in patients with obstructive renal disease. J Nucl Med 1994;35:840-845.
27Kabasakal L, Turoğlu HT, Onsel C, ve ark. Clinical comparison oftechnetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders. J Nucl Med. 1995;36:22422-8.
28Stoffel M, Jamar F, Van Nerom C, ve ark. Technetium-99m L,L-ethylenedicysteine clearance and correlation with iodine-125 orthoiodohippurate for the determination of effective renal plasma flow. Eur J Nucl Med. 1996 ;23:365-370.
29Kabasakal L, Halaç M, Alkan E, Ozçelik N, Uslu I. Reproducibility of technetium-99m ethylenedicysteine clearance. Eur J Nucl Med. 1999;26:900-902.
30de Kieviet W. Technetium radiopharmaceuticals: chemical characterization and tissue distribution of Tc-glucoheptonate using Tc-99m and carrier Tc-99. J Nucl Med. 1981;22:703-709.
31Lin TH, Khentigan A, Winchell HS. Tc-99m chelate substitute for organoradimercuricial renal agents. J Nucl Med 1974; 15: 34-35.
32Enlander D, Weber PM, dos Remedios LV. Renal cortical imaging in 35 patients: superior quality with Tc-99m-DMSA. J Nucl Med 1974;15:743-749.
33Handmaker H, Young BW, Lowenstein JM. Clinical experience with Tc-99m-DMSA (dimercaptosuccinic acid), a new renal-imaging agent. J Nucl Med. 1975;16:28-32.
34Schofner C. Cystourethrography: methodology, normal anatomy and pathology. J Urol 1970; 103: 92-103.
35Conway J, King L, Belman A, Thorson T. Detection of vesicoureteral reflux with radionuclide cystography. Am. J Roentgenol Radium Ther Nucl Med 1972; 115: 720-727.
36Bodei L, Müller-Brand J, Baum RP, ve ark. The joint IAEA, EANM and SNMMI practical guideance on peptide receotor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nuc Med Mol Imaging 2013; 40: 800-816.
37Hofman M, Binns D, Johnson V. ve ark. 68Ga-EDTA PET/CT imaging and plasma clearance of glomerular filtration rate quantification: comparison to conventional 51Cr-EDTA. J Nucl Med 2015; 56: 405-409.
38Hofman MS, Hicks RJ. Gallium-68 EDTA PET/CT for renal imaging. Semin Nucl Med 2016; 46: 448-461.
39Raveenthiran S, Esler R, Yaxley J, Kyle S. The use of 68Ga-PSMA PET/CT in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019; 46: 2280-2288.
